Immunogenicity and antitumor activity of the superlytic λF7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice
Loading...
Date
2018-06-28
Authors
Barati, Nastaran
Razazan, Atefeh
Nicastro, Jessica
Slavcev, Roderick
Arab, Atefeh
Mosaffa, Fatemeh
Nikpoor, Amin Reza
Badiee, Ali
Jaafari, Mahmoud Reza
Behravan, Javad
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Phage display technique has been increasingly researched for vaccine design and delivery strategies in recent years. In this study, the AE37 (Ii-Key/HER-2/neu 776–790) peptide derived from HER2 (human epidermal growth factor receptor protein) was used as a fused peptide to the lambda phage (λF7) coat protein gpD, and the phage nanoparticles were used to induce antitumor immunogenicity in a TUBO model of breast cancer in mice. Mice were immunized with the AE37 peptide displaying phage, λF7 (gpD::AE37) every 2-week intervals over 6-weeks, then the generated immune responses were evaluated. An induction of CTL immune response by the λF7 (gpD::AE37) construct compared to the control λF7 and buffer groups was observed in vitro. Moreover, in the in vivo studies, the vaccine candidate showed promising prophylactic and therapeutic effects against the HER2 overexpressing cancer in BALB/c mice.
Description
The final publication is available at Elsevier via http://dx.doi.org/10.1016/j.canlet.2018.03.030 © 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
Keywords
AE37, Antitumor immunogenicity, Becteriophage λF7, Breast cancer, HER2/neu, Vaccine